SCHEMBL17201654

SCHEMBL17201654

CCCCCCCCCCCCCCCCCCCCCCCCCCCc1cc(O)cc(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 1.00
CYP3A4 P08684 2/20 0.95
ESR1 P03372 2/20 0.63
ADRA2A P08913 2/20 0.63
ADORA3 P0DMS8 2/20 0.63
TACR2 P21452 2/20 0.63
SLC6A2 P23975 2/20 0.63
SLC6A4 P31645 2/20 0.63
SLC6A3 Q01959 2/20 0.63
KDM4E B2RXH2 1/20 0.63
ALDH1A1 P00352 1/20 0.63
LMNA P02545 1/20 0.63
SHBG P04278 1/20 0.63
TP53 P04637 1/20 0.63
HSPD1 P10809 1/20 0.63
ADRB3 P13945 1/20 0.63
HTR2C P28335 1/20 0.63
HSPE1 P61604 1/20 0.63
HIF1A Q16665 1/20 0.63
TST Q16762 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11737365 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
Cardol SCHEMBL406402 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL2464812 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL4448056 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL16432840 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL1914183 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL16431835 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL2468227 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL2178058 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3
SCHEMBL70057 1.00 PTGS2 (1.00) PTGS2CYP3A4ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-20220323372-A1 COMPOSITION FOR IMPROVING LIVER FUNCTION NITTO FUJI FLOUR MILLING CO., LTD. (JP) 2022-10-13 US disclosed
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
EP-3974026-A1 COMPOSITION FOR IMPROVING LIVER FUNCTION Nitto Fuji Flour Milling Co., Ltd. (JP) 2022-03-30 EP disclosed
WO-2020235546-A1 COMPOSITION FOR IMPROVING LIVER FUNCTION 日東富士製粉株式会社 (JP) 2020-11-26 WO disclosed
US-20190309289-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2019-10-10 US disclosed
US-10370654-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2019-08-06 US disclosed
US-20180320170-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2018-11-08 US disclosed
US-9944925-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. 2018-04-17 US disclosed
US-9737494-B2 Method of regulating circadian rhythm, and method of preparing circadian rhythm regulatory agent NAT'L INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 2017-08-22 US disclosed
US-20170095428-A1 AGENT FOR IMPROVING GLUCOSE TOLERANCE DISORDER NISSHIN SEIFUN GROUP (JP) 2017-04-06 US disclosed
US-20160186168-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2016-06-30 US disclosed
US-20150306045-A1 METHOD OF REGULATING CIRCADIAN RHYTHM, AND METHOD OF PREPARING CIRCADIAN RHYTHM REGULATORY AGENT NAT'L INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170095428-A1 AGENT FOR IMPROVING GLUCOSE TOLERANCE DISORDER GPR119, SLC2A3, SLC2A1 PTGS2 2926/4885CYP3A4 2916/4885ESR1 3384/4885
US-20220323372-A1 COMPOSITION FOR IMPROVING LIVER FUNCTION LIPC, OAT, GYS2 PTGS2 2997/4885CYP3A4 218/4885ESR1 4040/4885
US-20150306045-A1 METHOD OF REGULATING CIRCADIAN RHYTHM, AND METHOD OF PREPARING CIRCADIAN RHYTHM REGULATORY AGENT CRY1, PER2, ARNT PTGS2 1899/4885CYP3A4 262/4885ESR1 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.